We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AERI
2876
DELISTED
Aerie Pharmaceuticals
AERI
$94K ﹤0.01%
13,404
-15,700
-54% -$164K
OCUL icon
2877
Ocular Therapeutix
OCUL
$2.23B
$92K ﹤0.01%
13,260
-21,300
-62% -$165K
LAB icon
2878
Standard BioTools
LAB
$306M
$89K ﹤0.01%
22,761
-28,300
-55% -$132K
LTRX icon
2879
Lantronix
LTRX
$275M
$88K ﹤0.01%
11,200
EXTN
2880
DELISTED
Exterran Corporation
EXTN
$88K ﹤0.01%
29,500
+12,500
+74% +$49.5K
JNCE
2881
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$85K ﹤0.01%
10,194
-191,300
-95% -$1.58M
MNOV icon
2882
MediciNova
MNOV
$64.5M
$84K ﹤0.01%
31,500
SFT
2883
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
$84K ﹤0.01%
+2,454
New +$134K
PED icon
2884
PEDEVCO
PED
$161M
$83K ﹤0.01%
3,905
UUUU icon
2885
Energy Fuels
UUUU
$3.64B
$81K ﹤0.01%
10,570
-1,878
-15% -$15.9K
WYY icon
2886
WidePoint Corp
WYY
$113M
$81K ﹤0.01%
20,700
CTIC
2887
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$81K ﹤0.01%
32,700
KPRX icon
2888
Kiora Pharmaceuticals
KPRX
$11.4M
$77K ﹤0.01%
143
NGNE icon
2889
Neurogene
NGNE
$728M
$77K ﹤0.01%
802
-5
-0.6% -$609
OESX icon
2890
Orion Energy Systems
OESX
$79.7M
$77K ﹤0.01%
2,130
-1,380
-39% -$53.3K
INFI
2891
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$77K ﹤0.01%
34,444
-1,800
-5% -$4.52K
MLSS icon
2892
Milestone Scientific
MLSS
$48.1M
$76K ﹤0.01%
36,700
ALTO icon
2893
Alto Ingredients
ALTO
$329M
$75K ﹤0.01%
15,641
-1,300
-8% -$6.82K
AIOT
2894
PowerFleet Inc
AIOT
$420M
$75K ﹤0.01%
15,900
LFMD icon
2895
LifeMD
LFMD
$161M
$73K ﹤0.01%
18,900
SRT
2896
DELISTED
Startek Inc.
SRT
$73K ﹤0.01%
13,917
-300
-2% -$1.5K
RIDE
2897
DELISTED
Lordstown Motors Corp. Class A Common Stock
RIDE
$72K ﹤0.01%
1,393
-1,414
-50% -$103K
IQ icon
2898
iQIYI
IQ
$1.3B
$68K ﹤0.01%
+14,900
New +$105K
PHUN icon
2899
Phunware
PHUN
$43.2M
$68K ﹤0.01%
520
-1,136
-69% -$175K
QUAD icon
2900
Quad
QUAD
$502M
$67K ﹤0.01%
16,700

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.